Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids showed no clear difference in absence of nausea ( compared with placebo (low certainty).
1 finding from 1 review
Participant preference · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher participant preference ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher withdrawal any reason ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Lack of efficacy withdrawal · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoids changes withdrawal due to lack of efficacy ( compared with other anti‐emetic agent (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher withdrawal due to adverse event ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher absence of vomiting ( compared with placebo (low certainty).
1 finding from 1 review
Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids probably leads to higher absence of nausea and vomiting ( compared with placebo (moderate certainty).
1 finding from 1 review
Participant preference · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher participant preference ( compared with placebo (low certainty).
1 finding from 1 review
Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoids changes withdrawal any reason ( compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoids changes withdrawal due to adverse event ( compared with placebo (very low certainty).
1 finding from 1 review
Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids showed no clear difference in absence of nausea ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids showed no clear difference in absence of vomiting ( compared with other anti‐emetic agent (moderate certainty).
1 finding from 1 review
Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids showed no clear difference in absence of nausea and vomiting ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Cognitive function · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
1 finding from 1 review
Behavioural and psychological symptoms of dementia (BPSD) · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
1 finding from 1 review
Agitated or aggressive behaviours in dementia patients, measured on the Cohen‐Mansfield Agitation Inventory (CMAI) Scale (range 29 to 203, with 29 meaning no symptoms, and higher number of points indicating more severe symptoms)Â · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
1 finding from 1 review
Adverse events ‐ nervous system disorders ‐ total nervous system disorders ( · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
Comparison: cannabinoids showed no clear difference in adverse events ‐ nervous system disorders ‐ total nervous system… compared with placebo (low certainty).
1 finding from 1 review
Adverse events: psychological disorders · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
Comparison: cannabinoids showed no clear difference in adverse events ‐ psychiatric disorders ‐ total psychiatric disorders ( compared with placebo (low certainty).
1 finding from 1 review
Adverse event: gastrointestinal disorders at 1‐month (with actual · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
Comparison: cannabinoids showed no clear difference in adverse events ‐ gastrointestinal disorders ‐ total gastrointestinal… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: 1. General ‐ overall number of events · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
Comparison: cannabinoids showed no clear difference in adverse events ‐ general ‐ total general adverse events ( compared with placebo (low certainty).
1 finding from 1 review